Optimizing CKD Outcomes Through Fixed-Dose Combination Therapies

• Evaluating clinical rationale for combining complementary mechanisms in a single therapy to improve kidney and cardiovascular outcomes
• Reviewing evidence from recent trials demonstrating efficacy, safety, and tolerability of fixed-dose combinations in CKD populations
• Considering regulatory and formulation challenges for developing multi-agent therapies with predictable pharmacokinetics
• Exploring patient adherence, convenience, and real-world implementation benefits of fixed-dose combination strategies

Speakers:

Marvin Sinsakul

Associate Director, Clinical Development

AstraZeneca